Lupus Trials

​The Division of Rheumatology strives to understand more about lupus through research.  Please see the list below, which summarizes the st​udies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 

 

Study Name/IRB​#/PIBrief Description​Basic Eligibility​ CriteriaContact​

20170588

18-0907

Susan Boackle, MD

A phase 2, placebo controlled study to assess if targeting both T-cell and B-cell activity with an investigational bispecific antibody can help suppress inflammation associated with SLE.
  • Adult women or men (ages 18-75) with confirmed, active SLE.
  • Must be taking at least one but not more than two of the following SLE treatments: mycophenolate mofetil, azathioprine, methotrexate, hydroxychloroquine, chloroquine, dapsone, or quinacrine.
  • For subjects taking prednisone, the dose must be ≤ 20 mg/day


303-724-0581,
or email
Karen Franklin​ or Daniel Uy
SMILE (Study of Anti-Malarials in Incomplete Lupus Erythematosus)
20-0141
Susan Boackle, MD
 ​Use of an approved medication (hydroxychloroquine) to prevent development of additional clinical and immunologic features of SLE. This study includes a placebo group.
  • Teens or adults (ages 15-49) with an ANA titer of 1:80 or greater, plus one to two additional features of SLE.
303-724-0581,
or email
Karen Franklin​ or Hannah Meyer

Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.